A5086192559- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Renal and related cancers
- Epigenetics and DNA Methylation
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Eosinophilic Disorders and Syndromes
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Testicular diseases and treatments
- Neuroendocrine Tumor Research Advances
- Metastasis and carcinoma case studies
- Lung Cancer Research Studies
- Genital Health and Disease
- Tuberous Sclerosis Complex Research
- Eosinophilic Esophagitis
- Immune responses and vaccinations
- Ovarian cancer diagnosis and treatment
- Peptidase Inhibition and Analysis
- Vascular Tumors and Angiosarcomas
- Neuroblastoma Research and Treatments
Johns Hopkins University
2014-2025
Johns Hopkins Medicine
2017-2025
Johns Hopkins Hospital
2015-2025
Bladder Cancer Advocacy Network
2020-2024
Sidney Kimmel Comprehensive Cancer Center
2018-2024
Cornell University
2007-2023
Mount Sinai Hospital
2023
University of Baltimore
2018-2022
Heinrich Heine University Düsseldorf
2022
Edinburgh Cancer Research
2022
The miR-34 family is directly transactivated by tumor suppressor p53, which frequently mutated in human epithelial ovarian cancer (EOC). We hypothesized that expression would be decreased EOC and reconstituted might reduce cell proliferation invasion of cells.miR-34 was determined quantitative reverse transcription-PCR situ hybridization a panel 83 samples. Functional characterization accomplished reconstitution cells with synthetic pre-miR molecules followed determining changes...
The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 morphologic variants carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for using performed on 169 patients including 83 with nonmuscle invasive bladder cancer 86 muscle Staining scored intensity (0 to 3) extent (% positive cells) the histological score system, where >15 considered...
Thyroid transcription factor-1 (TTF-1) is a factor that plays role in the development and physiology of thyroid lungs. Expression TTF-1 used as marker lung clinically. Commercially available clones monoclonal antibodies, 8G7G3/1 SPT24, have been reported to different sensitivities for detection neoplasms origins. Although they are extensively daily practice, comprehensive comparative study these antibodies wide variety lacking. We examined expression primary tumors lung, prostrate, pancreas,...
To characterize immune cell expression among patients with non-muscle invasive bladder cancer (NMIBC) treated Bacillus Calmette-Guerin (BCG).Patients NMIBC intravesical BCG (2008-2015) were identified, and a tissue microarray was constructed using paired pre- post-BCG samples. Among undergoing BCG, cystoscopic evaluation began 3 months after initiating treatment to determine therapeutic response. IHC performed for CD8, CD4, FoxP3, PD-L1 (SP-142 22C3), PD-1. A full slide review of PD-L1+...
Recent observations suggest that p53 mutations are responsible not only for growth of primary tumors but also their dissemination. However, mechanisms involved in p53-mediated control cell motility and invasion remain poorly understood. By using the ovarian surface epithelium culture, we show conditional inactivation or expression its mutant forms results overexpression MET receptor tyrosine kinase, a crucial regulator invasive growth. At same time, cells acquire increased MET-dependent...
Eosinophilic solid and cystic (ESC) renal cell carcinoma (RCC) has recently been described as a potentially new subtype of RCC based upon morphologic immunohistochemical features. These neoplasms typically demonstrate architecture, the neoplastic cells contain voluminous eosinophilic cytoplasm with granular cytoplasmic stippling. There is frequently focal immunoreactivity for cytokeratin 20. Although initial cases all occurred in adult females had benign outcome, we expanded proposed...
We sought to determine if some unclassified renal cell carcinomas (RCCs) in children and young adults that are characterised by predominantly eosinophilic cytoplasm related the recently described succinate dehydrogenase (SDH)-deficient RCC, fumarate hydratase (FH)-deficient RCC or solid cystic (ESC) RCC.We reviewed 33 RCCs with patients aged 35 years younger. Immunohistochemistry (IHC) for SDHB, FH CK20 (a marker of ESC) was performed all cases. IHC 2-succinocysteine (2SC) on loss labelling....
Abstract In addition to its role as a TB vaccine, BCG has been shown elicit heterologous protection against many other pathogens including viruses through process termed trained immunity. Despite potential broadly protective little done determine if BCG-mediated immunity levels can be optimized. Here we re-engineer express high of c-di-AMP, PAMP recognized by stimulator interferon genes (STING). We find that overexpressing c-di-AMP elicits more potent signatures higher pro-inflammatory...
GPNMB (glycoprotein nonmetastatic B) and other TFE3/TFEB transcriptional targets have been proposed as markers for microphthalmia (MiT) translocation renal cell carcinomas (tRCCs). We recently demonstrated that constitutive mTORC1 activation via TSC1/2 loss leads to increased activity of TFE3/TFEB, suggesting the pathogenesis molecular tRCCs TSC1/2-associated tumors may be overlapping. examined expression in human kidney angiomyolipoma (AML) lines with TSC2 and/or produced using CRISPR-Cas9...
Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity well described but has not been correlated with response. In this retrospective single-center study, data from patients treated more than one dose EV between December 2017 and June 2022 were analyzed. Of 56 a median age 69 yr, 41 (73.2%) male 27 (48.2%) had any-grade skin toxicity. For all 51 evaluable by physician-assessed Response Evaluation Criteria...
Enfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to human monoclonal targeting nectin-4. No validated biomarker predictive or correlated with response exists EV. Cutaneous toxicity among the most common EV-related toxicities and typically emerges in early cycles. This retrospective experience patients cancer treated EV monotherapy evaluated whether cutaneous improved outcomes including...
ABSTRACT Background The Nectin‐4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous expression of this protein UC. There is limited data available regarding by immunohistochemistry prostate cancer, but interest a substantial number UC patients likely to receive EV have concomitant cancer. Methods was evaluated tissue microarrays...
We report 2 primary renal sarcomas demonstrating BCOR-CCNB3 gene fusions that have recently been identified in undifferentiated round cell of bone and soft tissue. These neoplasms occurred male children aged 11 12 years, both were cystic as a result entrapment dilatation native tubules. Both cases composed variably cellular bland spindle cells with fine chromatin set myxoid stroma separated by branching capillary vasculature. demonstrated immunoreactivity for BCOR, cyclin D1, TLE1, SATB2 the...
Genomic and transcriptome sequencing of bladder cancer (BLCA) has identified multiple molecular alterations during progression. Many these genetic epigenetic changes play a role in the progression this disease. Studies have subtypes muscle-invasive (MIBC) with different sensitivities to frontline therapy suggesting heterogeneity tumors importance characterization MIBC provide effective treatment. Specifically, it become increasingly evident, as demonstrated by The Cancer Genome Atlas...
We report 8 cases of a distinctive, previously undescribed renal cell carcinoma associated with somatic mutations in the neurofibromin 2 ( NF2 ) gene. All patients were adults, ranging from 51 to 78 years age and known sex 6 7 males. The carcinomas predominantly unencapsulated, all had rounded, nodular interface native kidney. neoplasms solid papillary architecture evident most (7/8), while 1 was only tubular. biphasic, characterized by larger smaller cells. cells clustered around basement...
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy
Renal cell carcinoma with fibromyomatous stroma (RCCFMS) include ELOC/TCEB1 -mutated renal (RCC) and those TSC1/2 / MTOR alterations. Besides morphologic similarity, most of these tumors is known to be diffusely positive for carbonic anhydrase IX cytokeratin 7 by immunohistochemistry. We previously showed strong diffuse expression GPNMB (glycoprotein nonmetastatic B) in translocation RCC eosinophilic neoplasms TSC1/2/MTOR retrospectively identified molecularly confirmed cases TCEB1/ELOC (7...